Across TCGA pan-cancer cohorts, SCT Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SCT data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher SCT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCT expression acts as an unfavorable survival marker.
KICH are the cancer types where SCT Mutation most reproducibly stratifies survival.